There is good clinical evidence that measuring renal functional reserve, i. e., the capacity of the kidney to increase filtration in response to the stimulus of a protein meal or amino acid infusion, allows the estimation of the functional state of the glomeruli of the kidney [1] [2][3][4]. In patients with Type 1 (insulin-dependent) diabetes mellitus in particular, impaired renal functional reserve indicates glomerular hyperfiltration [1, 4]. Recently, long-term restriction of dietary protein from 1.0 to 0.6 g. kg i day ~ was demonstrated as resulting in a significant increase in renal functional reserve in diabetic patients [2]. Two major questions follow from this observation: first, whether protein consumption in Type i diabetic patients with impaired renal functional reserve may be indeed increased in comparison to patients with normal renal functional reserve. Second, whether the effect of converting enzyme inhibition on renal functional reserve may be determined by the pre-existing state of glomerular function. We recently conducted a double-blind, randomized, placebo-controlled study [5] to examine the effect of captopril on renal haemodynamic response to amino acids in Type 1 diabetes. Twenty patients were enrolled (9 females, ]1males, age, 21-50 years, haemoglobin AI, 7.6-9.9 % [normal, < 8.0 %], blood pressure, < 140/90 mmHg, urinary albumin excretion, < 20 gg/min). 25 mg captopril or placebo were given 90 min prior to the 2-h infusion of 500 ml 10% amino acid solution. For the present re-evaluation, patients were divided into two groups: In Group i (10 patients), renal functional reserve was normal (increase in inulin clearance in response to the amino acid infusion by > + 15 %) [4]. In Group 2 (10 patients), renal functional reserve was impaired. Patients in Group 2 differed from Group 1 in increased base-line inulin clearance (mean .+ SEM, 165 + 17 vs 117 _+ 9 ml. rain t. 1.73 m 2-~, p < 0.05). Paraaminohippurate (PAH) clearance was not significantly different (602+ 61 vs 516 • ml.min -~. 1.73 rex-0. Moreover, patients in Group 2 differed from Group i in higher urinary urea excretion (0.28 _+ 0.04 vs 0.19 _+ 0.02 mmol/min, p < 0.05), in increased base-line glucagon levels (98 .+ 10 vs 63 + 8 ng/1, p < 0.05) and in slightly higher blood pressure (130.+4/86_+3 vs 119_+ 5/81 _+3 mmHg, p < 0.05 for systolic blood pressure). There were no differences in haemoglobin At, nor in plasma levels of human growth hormone or human atrial natriuretic peptide. In the placebo study, the amino acid infusion increased inulin and PAH clearance in Group I by maximally + 38 _+ 12 % and + 50 _+ 21%, respectively (both p < 0.05). In Group 2, there was a paradoxical decrease in both indexes by maximally -20 _+ 8 % and -10 _+ 6 %, respectively (both p<0.05 vs Group 1). After captopril, inulin clearance in Group l was 128 + 14 ml. rain-1.1.73 m 2-1 and PAH rose to 742_+97ml.min ~.1.73m 2 t (p<0.05 vs placebo). In Group2, inulin clearance fell to 119+12ml.min-l.l.73m 2 1 (p < 0.05 vs placebo) and PAH clearance was 810 + 140 ml.min ~. 1.73 m 2-~. After captopril, maximal rises in inulin and PAH clearance in response to the amino acid infusion were reduced in Group 1 to + 8 -+ 5 % (p < 0.05 vs placebo) and + 16 + 9 %, respectively. In contrast, captopril converted the responsiveness of both indexes in Group 2: inulin and PAH clearance rose by maximally + 21 _+ 15% (p < 0.05 vs placebo) and + 22 + 17 %, respectively. Thus, the effect of converting enzyme inhibition on renal functional reserve in pa-
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The criteria for establishing screening services are: the condition must be an important health problem, affecting an identifiable population. An effective treatment must be available and, as well as a suitable screening test, acceptable to the population. The natural history of the condition must be understood, and an early pre-symptomatic stage must exist during which treatment is effective. Finally, the screening and treatment must be cost effective.
All these criteria are true for diabetic retinopathy. It has been shown to be an important health problem, and the population at risk, all diabetic patients, is easily identifiable. During the last 30 years the natural history of the condition has been clearly described, and in the 1970's and early 1980's randomised controlled clinical trials have amply proved the value of photocoagulation [3] [4] [5] [6] [7] . In an analysis of previous papers Rohan et al. [8] noted an average reduction of blindness by 73% (range 61 to 85 %). The long-term effectiveness of treatment has also been shown [9, 10] . Not only is blindness decreased, but the frequent occurrence of temporary visual loss due to recurrent vitreous haemorrhages is also reduced.
Is there a suitable screening test? Use of direct and indirect ophthalmoscopy through a dilated pupil will allow the identification of most patients who require treatment. Retinal photography using the non-mydriatic camera (though preferably with mydriasis), standard retinal photography preferably with stereo pictures of the macula, fluorescein angiography and slit lamp biomicroscopy all have their place in determining whom to treat, when to treat, and what to treat. When to use these methods and who should use them has long been a bone of contention. A recent workshop at the Hammersmith Hospital in London addressed these problems. The workshop was convened under the aegis of the European regions of the World Health Organisation (WHO) and the International Diabetes Federation, as a follow-up of the St. Vincent Declaration of 1989, which pledged to implement policies which will reduce the mortality and morbidity due to diabetes in Europe [11] . The workshop, at which ophthalmologists and diabetologists represented 2l European countries produced a consensus document on both screening and treatment [12] .
There was uniform agreement about the importance of screening programmes. These have to be staffed by adequately trained personnel, who have direct access to treatment facilities. The diabetic patients have to be identified and persuaded to avail themselves of these screening procedures. All this requires time, organisation and atso money. In order to convince the health authorities, with limited budgets that the investment in screening is cost effective we have to produce figures. Such figures are available from Scotland in 1983 [13] , and from the USA, in 1989 [14] . Both these studies indicate that the financial expenditure involved in identifying and treating one patient at risk of blindness is approximately 1/10 of the cost of maintaining this patient and his family on social benefit for the first year alone. This does not take into account the expenses of mobility training, teaching of Braille and re-training many of the sufferers. Nor does it take into account that blind patients and their families have to be supported for many years. Most important of all it does not take into account the improved quality of life maintaining vision confers.
The WHO will distribute the documents produced to the various European governments. The diabetologists and the ophthalmologists are already aware of the importance of screening. Thus, double pressure, from above and below, should force health authorities to support screening programmes. But organisation of these, implementation of the aims of the St.Vincent Declaration [11] to reduce the incidence of new blindness by one third in the next 5 years, remains in the hands of the doctors. Hopefully we are ready for this huge but important task.
Yours sincerely, E. M. Kohner and M. Porta
